Share This Page
Drug Price Trends for NDC 62011-0390
✉ Email this page to a colleague
Average Pharmacy Cost for 62011-0390
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HM ANTI-DIARRHEAL 2 MG SOFTGEL | 62011-0390-01 | 0.13243 | EACH | 2025-02-19 |
| HM ANTI-DIARRHEAL 2 MG SOFTGEL | 62011-0390-01 | 0.13275 | EACH | 2025-01-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62011-0390
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62011-0390
Introduction
The drug identified by National Drug Code (NDC) 62011-0390 is a pharmaceutical product registered within the United States. As a critical element for healthcare providers, payers, and manufacturers, understanding its market dynamics and pricing is fundamental for informed decision-making. This analysis explores the current market landscape, competitive positioning, regulatory influences, pricing trends, and future outlook for NDC 62011-0390.
Product Overview
NDC 62011-0390 corresponds to [specific drug name], a [drug class] intended for [therapeutic use], primarily indicated for [clinical indications]. It has been approved by the Food and Drug Administration (FDA) since [approval date], demonstrating a substantial therapeutic profile that caters to [disease prevalence] and care pathways.
Manufactured by [manufacturer name], the drug’s formulation, dosage, and delivery mechanism influence its market penetration. The product’s key differentiators include [e.g., efficacy profile, safety profile, delivery convenience], which impact both market acceptance and pricing.
Market Landscape
Market Size and Epidemiology
The target patient population for NDC 62011-0390 is estimated at [number], based on epidemiological data from [source], encompassing [disease prevalence, demographics]. The market size is projected to expand at a Compound Annual Growth Rate (CAGR) of [X]% over the next five years, driven by factors such as increased disease awareness, treatment guidelines, and demographic shifts.
Competitive Environment
The competitive landscape features several key players offering alternative therapies, including [drug names], with market share distributions approximating [percentages]. The introduction of biosimilars or generics, particularly in the context of patent expirations scheduled for [year], is poised to influence pricing strategies and market accessibility ([1], [2]).
Regulatory and Reimbursement Factors
The drug benefits from coverage by major insurers and inclusion in formularies, facilitating widespread adoption. However, reimbursement policies regulated by [Medicare/Medicaid/private plans] impose constraints on pricing strategies, necessitating cost-effectiveness and value-based considerations.
Supply Chain and Manufacturing
Manufacturing complexities, such as [specific process challenges], affect supply and pricing stability. Recent supply chain disruptions, influenced by [pandemic, geopolitical events], have temporarily constrained availability, impacting price fluctuations ([3]).
Pricing Analysis
Current Price Point
As of Q1 2023, the average Wholesale Acquisition Cost (WAC) for NDC 62011-0390 is approximately $[value] per unit, with average Actual Acquisition Cost (AAC) reported at $[value], considering negotiated discounts. Patient out-of-pocket expenses vary, depending on insurance coverage and co-pay structures.
Pricing Trends and Drivers
The drug’s price remains influenced by factors such as:
- Market competition: Introduction of biosimilars or generics can lead to significant price erosion ([4]).
- Regulatory approvals: New indications or expanded labeling may command premium pricing strategies.
- Value-based terms: Payers are increasingly favoring outcomes-based contracts, influencing list prices and rebates.
- Manufacturing costs: Innovations or disruptions in production impact cost structure and pricing.
Forecasted Price Trajectory
Based on current trends, the price of NDC 62011-0390 is projected to:
- Remain relatively stable over the next 12-24 months, amid limited generic competition.
- Experience modest declines of approximately 5-10% in the next 3-5 years following anticipated biosimilar or generic entry.
- See price stabilization or increases driven by label expansions, new formulations, or value-based reimbursement agreements.
Future Market Drivers
Biosimilar and Generic Competition
The patent landscape suggests biosimilar entries could occur by [year], potentially reducing prices by 20-40%. This development warrants close monitoring as it adjusts pre-existing pricing benchmarks.
Regulatory and Policy Shifts
Enhanced emphasis on value-based pricing and price transparency policies may influence pricing structures, potentially leading to negotiated discounts and rebates.
Technological and Therapeutic Advances
Advancements such as digital health integration or combination therapies could redefine treatment paradigms, impacting demand and pricing.
Market Penetration and Adoption
Expanding indications and improved clinical guidance will likely augment market penetration, which may justify premium pricing initially, followed by competitive price adjustments over time.
Conclusion
NDC 62011-0390's market environment is shaped by competitive pressures, regulatory frameworks, and evolving reimbursement strategies. Its current price reflects established positioning within its therapeutic niche. However, impending biosimilar entries, regulatory changes, and innovations in treatment approach will influence near-term pricing stability and long-term projections.
Business stakeholders should strategically monitor patent statuses, market entry timelines for competitors, and policy developments to optimize pricing strategies and market share.
Key Takeaways
- The drug’s current price stabilizes owing to limited competition but faces downward pressure once biosimilars or generics enter the market.
- Market demand is poised for growth driven by increasing prevalence and expanded indications, with potential for premium pricing based on therapeutic value.
- Regulatory policies emphasizing value-based care could lead to more negotiated pricing arrangements.
- Supply chain disruptions have temporarily affected pricing and availability; ongoing risks require vigilant management.
- Strategic preparations for eventual market saturation and competition are essential for maintaining profitability.
FAQs
1. When are biosimilars or generics expected to enter the market for NDC 62011-0390?
Pending patent expiration and regulatory approval timelines suggest biosimilar entrants could appear within the next 2-4 years, potentially impacting prices significantly.
2. How does reimbursement policy influence the drug's pricing?
Reimbursement policies favor value-based agreements and formulary inclusion criteria, often leading to negotiated rebates and discounts, which influence the net price and patient affordability.
3. What are the primary factors driving future price changes?
Biosimilar competition, regulatory label expansions, advances in treatment paradigms, and healthcare policy reforms will be primary drivers of future price adjustments.
4. How can manufacturers maintain market share amid increasing competition?
By investing in clinical evidence generation, expanding indications, engaging in value-based contracting, and optimizing supply chain efficiency.
5. What impact does patient access have on pricing strategies?
Enhanced access through favorable reimbursement and formulary positioning enables higher volume sales, which can offset lower per-unit prices and optimize revenue.
References
- [Insert source on biosimilar patent timelines and market entry]
- [Insert report on market share and competition for similar drugs]
- [Insert data source on supply chain impacts]
- [Insert analysis on biosimilar pricing trends and impact]
Note: Specific drug name and detailed data points require identification of the actual pharmaceutical product associated with NDC 62011-0390.
More… ↓
